BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer

Cell Cycle

Volumn 13, Issue 16, 2014, Pages 2564-2571

  Li, Da ^a   Chen, Na Na ^b   Cao, Ji Min ^c   Sun, Wu Ping ^d   Zhou, Yi Ming ^d   Li, Chun Yan ^c   Wang, Xiu Xia ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^d NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

BRCA1; NAD; NADH; Nampt; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ARTICLE; CANCER GROWTH; CELL LEVEL; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; METABOLISM; NUCLEOTIDE SEQUENCE; OVARIAN CANCER CELL LINE; OVARY CANCER; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN METHYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84907486220     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2015.942208     Document Type: Article

References (28)

1. Lech A, Daneva T, Pashova S, Gagov H, Crayton R, Kukwa W, Czarnecka AM, Szczylik C. Ovarian cancer as a genetic disease. Front Biosci 2013; 18:543-63; http://dx.doi.org/10.2741/4119
2. Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc 2010; 85:1111-20; PMID: 21123638; http://dx.doi.org/10.4065/mcp.2010.0414
3. Schouten LJ, van Dijk BA, Lumey LH, Goldbohm RA, van den Brandt PA. Energy restriction during childhood and early adulthood and ovarian cancer risk. PLoS One 2011; 6:e27960; PMID: 22132180; http://dx.doi.org/10.1371/journal.pone.0027960
4. Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lachuer J, Venezia ND. BRCA1-dependent translational regulation in breast cancer cells. PLoS One 2013; 8:e67313; PMID: 23805307; http://dx.doi.org/10.1371/journal.pone.0067313
5. Li D, Bi FF, Cao JM, Cao C, Li CY, Yang Q. Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer. J Exp Clin Cancer Res 2013; 32:102; PMID: 24321281; http://dx.doi.org/10.1186/1756-9966-32-102
6. Bi FF, Li D, Cao C, Li CY, Yang Q. Regulation of angiotensin II type 1 receptor expression in ovarian cancer: a potential role for BRCA1. J Ovarian Res 2013; 6:89; PMID: 24321324; http://dx.doi.org/10.1186/1757-2215-6-89
7. Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou YM, Cao C, Li CY, Liu B, Yang Q. Epigenetic repression of phosphatidylethanolamine, N-methyltransferase (PEMT) in BRCA1-mutated breast cancer. Oncotarget 2014; 5:1315-25. PMID: 24675476
8. Li D, Bi FF, Cao JM, Cao C, Li CY, Liu B, Yang Q. Poly (ADP-ribose) polymerase 1 transcriptional regulation: A novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer. Oncotarget 2014; 5:291-7; PMID: 24448423
9. Li D, Bi FF, Cao JM, Cao C, Liu B, Yang Q. Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between E2F1 motif hypermethylation and loss of histone H3 lysine 9 acetylation. Mol Cancer 2014; 13:26; PMID: 24502362; http://dx.doi.org/10.1186/1476-4598-13-26
10. Pan LZ, Ahn DG, Sharif T, Clements D, Gujar SA, Lee PW. The NAD synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target. Cell Cycle 2014; 13:1-8; PMID: 24231773; http://dx.doi.org/10.4161/cc.28128
11. Chiarugi A, Dölle C, Felici R, Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 2012; 12:741-52; PMID: 23018234; http://dx.doi.org/10.1038/nrc3340
12. Zhang B, Chen J, Cheng AS, Ko BC. Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase (TERT) gene in hepatocellular carcinoma cells. PLoS One 2014; 9:e84931; PMID: 24416313; http://dx.doi.org/10.1371/journal.pone.0084931
13. Mahajan SS, Scian M, Sripathy S, Posakony J, Lao U, Loe TK, Leko V, Thalhofer A, Schuler AD, Bedalov A, et al. Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors. J Med Chem 2014; 57:3283-94; PMID: 24697269; http://dx.doi.org/10.1021/jm4018064
14. Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 2014; 25:138-45; PMID: 24388149; http://dx.doi.org/10.1016/j.tem.2013.12.001
15. Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, Spentzos D, Miron A, Yassin YA, Lee BT, Wulf GM. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res 2009; 69:1273-8; PMID: 19190334; http://dx.doi.org/10.1158/0008-5472.CAN-08-2954
16. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells. Int J Cancer 2009; 125:2820-8; PMID: 19551867; http://dx.doi.org/10.1002/ijc.24684
17. Kang HJ, Yi YW, Kim HJ, Hong YB, Seong YS, Bae I. BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site. Cell Death Dis 2012; 3:e336; PMID: 22739988; http://dx.doi.org/10.1038/cddis.2012.78
18. Werner H, Bruchim I. IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol 2012; 13:e537-44; PMID: 23182194; http://dx.doi.org/10.1016/S1470-2045(12)70362-5
19. Wen J, Li R, Lu Y, Shupnik MA. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene 2009; 28:575-86; PMID: 18997820; http://dx.doi.org/10.1038/onc.2008.405
20. Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM. Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Mol Endocrinol 2009; 23:1135-46; PMID: 19389812; http://dx.doi.org/10.1210/me.2008-0347
21. Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P, Gompel A, Bracaps. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. Breast Cancer Res Treat 2013; 142:283-96; PMID: 24166279; http://dx.doi.org/10.1007/s10549-013-2722-8
22. Ng F, Tang BL. When is Sirt1 activity bad for dying neurons? Front Cell Neurosci 2013; 7:186; PMID: 24167473; http://dx.doi.org/10.3389/fncel.2013.00186
23. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer 2010; 1:812-21; PMID: 21779467; http://dx.doi.org/10.1177/1947601910383418
24. Ito K. Impact of post-translational modifications of proteins on the inflammatory process. Biochem Soc Trans 2007; 35:281-3; PMID: 17371260; http://dx.doi.org/10.1042/BST0350281
25. Deng Y, Liu J, Han G, Lu SL, Wang SY, Malkoski S, Tan AC, Deng C, Wang XJ, Zhang Q. Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. Oncogene 2010; 29:6603-8; PMID: 20818429; http://dx.doi.org/10.1038/onc.2010.406
26. Di LJ, Fernandez AG, De Siervi A, Longo DL, Gardner K. Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat Struct Mol Biol 2010; 17:1406-13; PMID: 21102443; http://dx.doi.org/10.1038/nsmb.1941
27. Tanikawa M, Wada-Hiraike O, Nakagawa S, Shirane A, Hiraike H, Koyama S, Miyamoto Y, Sone K, Tsuruga T, Nagasaka K, et al. Multifunctional transcription factor TFII-I is an activator of BRCA1 function. Br J Cancer 2011; 104:1349-55; PMID: 21407215; http://dx.doi.org/10.1038/bjc.2011.75
28. Hiraike H, Wada-Hiraike O, Nakagawa S, Koyama S, Miyamoto Y, Sone K, Tanikawa M, Tsuruga T, Nagasaka K, Matsumoto Y, et al. Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer 2010; 102:1061-7; PMID: 20160719; http://dx.doi.org/10.1038/sj.bjc.6605577